Figure 4
From: CRTAC1 identified as a promising diagnosis and prognostic biomarker in lung adenocarcinoma
CRTAC1 upstream regulatory mechanism analysis, mutational analysis, methylation analysis and single-cell analysis. (A) By overlap of TFs based on JASPAR, GTRD, and AnimalTFDB, five TFs were ultimately identified. (B) Scatter plot showed a statistically significant negative correlation between the levels of CRTAC1 and TFAP2A expression. (C) Kaplan‐Meier survival curves of TCGA-LUAD patients showed the low TFAP2A mRNA expression group exhibited a more favorable prognosis compared to high expression group. (D) By overlap of miRNA based on miRDB, TargetScan, and mirwalk, seven miRNA were ultimately identified. (E) Frequency and type of CRTAC1 mutations in LUAD. (F) Scatter plot showed a statistically significant negative correlation between CRTAC1 expression and TMB in LUAD. (G) The methylation expression levels of CRTAC1 in LUAD tissues are significantly higher compared to those in normal tissues. (H) Single-cell RNA sequencing location analysis of CRTAC1. (I) CRTAC1 was enriched in pulmonary alveolar type II cell clusters. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, ns, no significance. TF, transcription factor; TMB, tumor mutation burden.
